The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jury, E. C.
Right arrow Articles by Ehrenstein, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jury, E. C.
Right arrow Articles by Ehrenstein, M. R.
Right arrowPubmed/NCBI databases
*Domain
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*Lupus
The Journal of Immunology, 2006, 177: 7416-7422.
Copyright © 2006 by The American Association of Immunologists, Inc.

Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus1

Elizabeth C. Jury2, David A. Isenberg, Claudia Mauri3 and Michael R. Ehrenstein2,3

Department of Medicine, Centre for Rheumatology, University College London, United Kingdom

Loss of tolerance to self-Ags in patients with systemic lupus erythematosus (SLE), a prototypic autoimmune disease, is associated with dysregulation of T cell signaling, including the depletion of total levels of lymphocyte-specific protein kinase (Lck) from sphingolipid-cholesterol-enriched membrane microdomains (lipid rafts). Inhibitors of 3-hyroxy-3-methylgluteryl CoA reductase (statins) can modify the composition of lipid rafts, resulting in alteration of T cell signaling. In this study, we show that atorvastatin targets the distribution of signaling molecules in T cells from SLE patients, by disrupting the colocalization of total Lck and CD45 within lipid rafts, leading to a reduction in the active form of Lck. Upon T cell activation using anti-CD3/anti-CD28 in vitro, the rapid recruitment of total Lck to the immunological synapse was inhibited by atorvastatin, whereas ERK phosphorylation, which is decreased in SLE T cells, was reconstituted. Furthermore, atorvastatin reduced the production of IL-10 and IL-6 by T cells, implicated in the pathogenesis of SLE. Thus, atorvastatin reversed many of the signaling defects characteristic of SLE T cells. These findings demonstrate the potential for atorvastatin to target lipid raft–associated signaling abnormalities in autoreactive T cells and provide a rationale for its use in therapy of autoimmune disease.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 The Arthritis Research Campaign supports EC.J. (Project Grant 13967).

2 Address correspondence and reprint requests to Dr. Elizabeth Jury or Dr. Michael Ehrenstein, Centre for Rheumatology Research, University College London, Windeyer Institute of Medical Science, 46 Cleveland Street, London W1P 4JF, U.K. E-mail addresses: e.jury{at}ucl.ac.uk or m.ehrenstein{at}ucl.ac.uk

3 C.M. and M.R.E. contributed equally to this work.

4 Abbreviations used in this paper: HMG-CoA, 3-hyroxy-3-methylgluteryl CoA; SLE, systemic lupus erythematosus; Lck, lymphocyte-specific protein tyrosine kinase; LAT, linker for activation of T cell; CTB, cholera toxin B; DRM, detergent-resistant membrane.




This article has been cited by other articles:


Home page
J. Immunol.Home page
E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al.
Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway
J. Immunol., September 1, 2008; 181(5): 3524 - 3534.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S. Datta and C Mauri
Signalling defects and cellular interactions (2)
Lupus, March 1, 2008; 17(3): 247 - 250.
[PDF]


Home page
J. Immunol.Home page
E. C. Jury, J. Eldridge, D. A. Isenberg, and P. S. Kabouridis
Agrin Signalling Contributes to Cell Activation and Is Overexpressed in T Lymphocytes from Lupus Patients
J. Immunol., December 1, 2007; 179(11): 7975 - 7983.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
K. Tenbrock, Y.-T. Juang, V. C. Kyttaris, and G. C. Tsokos
Altered signal transduction in SLE T cells
Rheumatology, October 1, 2007; 46(10): 1525 - 1530.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.